20 citations
,
July 2024 in “Archives of Dermatological Research” This study evaluated the effectiveness of dupilumab in promoting hair regrowth in 20 pediatric patients with alopecia areata (AA) and atopic dermatitis (AD), aged 5-16 years. Over a follow-up period averaging 67.6 weeks, patients showed significant improvement in hair regrowth, as measured by the Severity of Alopecia Tool (SALT), with mean scores decreasing from 54.4 at baseline to 20.4 at 48 weeks and further to 2.2 beyond 72 weeks. The study found correlations between baseline SALT scores and disease duration, as well as between baseline IgE levels and improvement in SALT scores. Dupilumab was well-tolerated, with no new safety concerns, suggesting its potential as a safe treatment for pediatric AA, highlighting the need for larger clinical trials.
45 citations
,
May 2024 in “International Journal of Molecular Sciences” Alopecia areata is caused by immune attacks on hair follicles, affecting hair growth and quality of life.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
April 2023 in “Medizinische Genetik” New research has found 14 genes linked to the risk of developing alopecia areata, improving understanding and treatment options.
35 citations
,
November 2022 in “The Journal of Dermatology” Alopecia areata is becoming more common in Japan, with a need for better treatments, especially for severe and pediatric cases.
37 citations
,
December 2021 in “Cells” Alopecia areata severity and treatment response are linked to specific cytokine levels.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
14 citations
,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
31 citations
,
July 2021 in “ImmunoTargets and therapy” Alopecia areata is an incurable autoimmune condition causing hair loss, with research aiming for better treatments.
55 citations
,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.
57 citations
,
April 2019 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata involves immune system imbalances that may lead to depression and anxiety.
148 citations
,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
100 citations
,
July 2018 in “Journal of The American Academy of Dermatology” People with alopecia areata often have other health issues like skin diseases, metabolic syndrome, stomach infections, lupus, anemia, thyroid problems, mental health issues, vitamin D deficiency, and hearing and eye problems.
58 citations
,
July 2018 in “Journal of Allergy and Clinical Immunology” Alopecia areata severity is linked to increased TH1 and TH2 activity.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
MagicBold 